Patrick Barry Email & Phone Number

New York, NY, US

Malvern, PA, US

• Lead all commercial activities across 3 US business segments and a Canadian affiliate, with full P&L responsibility for approximately $2B in revenue. Acting in a Chief Commercial Officer (CCO) role, successfully.
• Serve as a Section 16 Named Executive Officer reporting directly to the CEO while managing 8 direct reports, ~450 personnel, and an OpEx budget of more than $300M annually. Lead the Commercial Operations Leadership.
• Drive the portfolio strategy and guide investment decisions and valuation work for new products, indications, and product planning opportunities. Oversee the Portfolio Review Committee process, which is responsible for.
• Maintain responsibility for 3 Centers of Excellence supporting key operational functions, including managed care, patient support services, value and pricing, trade, forecasting, sales and marketing operations.
• Stabilized the XIAFLEX franchise, restored growth in the wake of the pandemic, and advanced the development of multiple Life Cycle Management (LCM) projects, which solidified and repositioned the branded segment as a.
• Developed and executed a portfolio strategy that transformed the Sterile Injectable Segment. Since 2020, reloaded the pipeline to build a more durable and differentiated portfolio while simultaneously launching.

Malvern, PA, US

• Promoted in recognition of the performance transformation of Branded Pharmaceuticals, which repositioned the segment as a primary growth driver for Endo. Led segment commercial activities and maintained full.
• Managed 6 VP-level direct reports, 7 key functions including sales, marketing, patient access, advanced analytics and commercial ops, and had oversight of an annual sales and marketing budget of $250M. Served as.
• Developed and launched transformational growth strategies that ignited double-digit growth for three consecutive years, including 11% growth in 2017, 11% growth in 2018, and 17% growth in 2019. Exceeded internal and.
• Built and executed an enterprise-wide launch readiness plan that enabled cross-functional execution, achieved the first and only FDA approved injectable for cellulite, and stood up a new medical aesthetics business unit.

Malvern, PA, US

• Led a major strategic transformation of the Branded organization from a legacy concentration on pain management to a highly focused specialty biopharma business. Managed all commercial activities within the branded.
• Resurrected XIAFLEX, a mid-life cycle biologic with flat to declining growth, increased revenue by +20% in 2018, and repositioned the product as a key driver of growth with $1B in potential. Revamped the marketing.
• Championed an engagement and communication strategy that revitalized the culture, improved accountability, enhanced commercial execution, drove performance, and increased sales team engagement to 90%+.
• Achieved industry-leading turn-around times and dispense rates by delivering next-level capabilities in HUB patient support services, field reimbursement, and mastered distribution channels.

Paris, France, FR

• Launched the new General Medicines business unit as part of a global reorganization, provided complete commercial oversight for branded businesses in renal, allergy, biosurgery and generic product sales across the US.

Paris, France, FR

• Selected to take on a newly created role to lead three complex specialty business units, including Oncology, Renal, and Biosurgery, with $2.3B in combined revenues. Led the integration of the BUs into the North.
• Built an innovative portfolio segmentation and investment strategy, created flexible commercial and investment models, and surpassed budget performance and profit contribution objectives by 106% of plan.
• Turned around the Oncology portfolio and achieved double market growth (15%+) for JEVTANA. Protected $800M+ in Renal sales revenue and preserved market leadership. Restored performance in the struggling Biosurgery.

Paris, France, FR

• Led the overall brand strategy for the division, headed sales and marketing for Multaq and AUVI-Q, and exceeded financial targets for the cardiovascular franchise. Managed a team of 5 direct reports, led sales and.
• Managed pre-commercialization and product launch activities for a novel oral anticoagulant (NOACs), PCSK9 inhibitor, a new epinephrine auto-injector, and Sanofi/Regeneron partnered monoclonal antibody products.
• Served as the Commercial Leader for Multaq between 2011 and 2012, reshaped the commercial plan for the product and surpassed all revenue goals.

Paris, France, FR

Paris, France, FR

Paris, France, FR

Paris, France, FR

Master Of Business Administration - Mba

Bachelor Of Arts, Public Relations & Marketing